Keywords
DDS
Resistance
Mycobacterium Leprae
Resistance
Mycobacterium Leprae
How to Cite
1.
COSTA HC, OPROMOLLA DVA, MADEIRA S, MARQUES FB, MARTELLI ACC, URA S. Prevalência de sulfono resistência em pacientes hansenianos do município de Bauru, estado de São Paulo. Hansen. Int. [Internet]. 1993 Nov. 30 [cited 2024 Dec. 4];18(1/2):05-10. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35465
Abstract
The aim of this study was to determine the prevalence of DDS resistance in lepromatous leprosy patients in Baum, São Paulo. In a population of 349 of such patients (205 with more than 5 years of treatment and thus in a high risk of developing resistance) 30 (14.63%) showed clinical signs of possible resistance (Bl of 3+ or higher). 10 patients presented bacilli resistant to DDS 2,86%). For this reason , authors conclude that nationwide implementation of MDT is of utmost importance.
References
1. ALMEIDA, J.G.; CHRISTIAN, M.; CHACKO, C.J.G.; TAYLOR, P.M. & FRITSCH, E.P. Studies on dapsone resistant Mycobacterium leprae in leprosy patients of Gudiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Center, Karigiri. 2. A progress report. Leprosy Rev. 56: 265-78, 1985.
2. BAOHONG, J.; JIAKUN, Z.; YUHONG, H.; GUOXING, N.; & RENBAO, Z. Secondary dapsone resistant leprosy in Shangai municipality. Leprosy Rev. 54:197-202,1983.
3. BAQUILON, G.; FERRACCI, C.; VAN-LOO, G.; PATTYN, S.R. Further results on dapsoneresistant leprosy in Bamako (Mali). Leprosy Rev. 54:19-21, 1983.
4.BECHELLI, L.M. Experiência brasileira com a sulfonoterapia: relatório do Dispensário nº 2 da sede do D.P.L. Arq. min. Leprol.
12(4):286-294, 1953,
5.BOURLAND, J.; VAN-LOO, G.; & PATTYN, S.R. Dapsone resistant leprosy in Burundi. Leprosy Rev. 54:239-42, 1983.
5. CHAUSSINAND, R. Aspect atue) du probleme de la lepra. Mt. J. Leprosy20(2): 229-238, 1952.
7. CONGRESSO INTERNACIONAL DE LEPROLOGIA, 6º, MADRID, 1953, Memórias, Madrid, 1953.
7. CONGRESSO INTERNACIONAL DE LEPROLOGIA, 7º , TOKIO, 1958, Memórias. Toldo, 1958.
9. COSTA, H.C.; SOUZA, L.C.D.; SAVRON, V.B.; PRADO, D.A.C. & LOSNAK, L.M. Procedimentos utilizados para a manutenção de linhagem isogênica decamundongos Mus musculus, estirpe BALB/c, para o uso no estudo da resistência do Mycobacterium leprae à
Diamino difenil sulfona (DDS) Salusvita 8(1):69-71, 1989.
10. COSTA, H.C.; LOSNAK, L.M.; MADEIRA, S.; COELHO, A.A.M.; WINCE, P.S.; SAVRON, V.B. Curva de crescimento padrão do
Mycobacterium leprae em coxim plantar de camundongos Mus musculus, estirpe BALB/c, isogênicos, do biotério do Instituto
Lauro de Souza Lima, Bauru, Estado de São Paulo. Salusvita 9(1):01-07, 1990.
11. DAVEY, T.F. Progress with new anti-leprosy drugs. In: International Leprosy Congress, 7°, Tokio, 1958, Transactions, Tokio, 1959.
p. 252-259.
12. DAVIDSON, J.A. Isoniazid alone and combined with triosemicarbazone. Leprosy Rev. 24:104-106, 1955.
13. FLOCH, H. La sulfone resistance de bacile de Hansen. Arch. Inst. Pasteur Guyane French.429: 1947.
14. GARROD, J.M.B. Colonial Medical Research Committe, 15th Annual Report, 1959, 1960. nº 2 da sede do D.P.L. Arq. min. Leprol.
12(4):286,1953.
15. GUINTO,R.S.; CELLONA, R.V.; FAJARDO, T.T. & CRUZ, E.C. dela. Primary dapsone resistant leprosy in Cebu, Philipines. Int. J. Leprosy 49(4): 427-430, 1981.
16. JOPLING, R. The treatment of leprosy. Pos graduated Medical Journal 136: 634, 1960.
17. LEVY, L.; RUBIN, G.S. & SHESKIN, J. The prevalence of dapsone resistant leprosy in Israel. Leprosy Rev, 4&107-12, 1977.
18. LOWE, J. The treatment of leprosy with TBI/698: A report based on 38 months experience. Leprosy Rev. 24:186-199, 1954.
19. MARIANO, J. Dez anos de experiência com a sulfonoterapia. Arq. min. Leprol. 16(2):93-107, 1956.
20. MEADE, T.W.; PEARSON, J.M.H.; REES, R.J.W. & NORTH, W.R.S. The epidemiology of sulphone resistant leprosy. Int. J. Leprosy 41(4):684, 1973.
21. MIRANDA, R.N. Recaída de caso de lepra lepromatosa. Arq. Paranaense de Leprol, 2(2):51, 1953.
22. MOURA, A.M. & ROCHINE, S. Vinte casos de recaída entre doentes transferidos para tratamento ambulatorial. Arq. Paranaense
de Leprol. 2(2): 47, 1953.
23. OPROMOLLA, D.V.A. Terapêutica multidroga. An. bras. Dermatol 65(1):37-40, 1990.
24. PEARSON, J.M.H.; HAILE, G.S.; BARNETSON, R.St.C. & REES, R.J.W. Dapsone-resistant leprosy in Ethiopia. Leprosy Rev. 50:183-99, 1979.
25. PEARSON, J.M.H.; REES, R.J.W.; WATERS, M.F.R. Sulphone resistance in leprosy. A review of one hundred proven clinical cases.
Lancet 2.69-72, 1975.
26. PETERS, J.H.; SHEPARD, C.C.; GORDON, G.R.; ROJAS, A.V. & ELIZONDO,D.S. The incidence of DDS resistance In lepromatous
patients in Costa Rica: their metabolic disposition of DDS. Int. J. Leprosy 44:143-51,1976.
27. PETTIT, J.H.S. & REES, R.J.W. Sulfone resistance in leprosy. An experimental and clinical study. LANCET 2. 673, 1964.
28. QUAGLIATO, R. O problema das reativações nos dispensários de lepra. Rev. bras. Leprol. 23(1): 83-113, 1955.
29. RABELLO, F.G. Simpósio sobre experiência brasileira com a sulfonoterapia. Arq. min. Leprol. 12(4):285-426, 1953.30. SHEPARD, C.C. The experimental disease that follows the injection of human leprosy bacilli into foot pads of mice. J. exp. Med. 112:445-54, 1960.
31. SOUZA LIMA, L. & ARANTES, F.R. Resistência do bacilo de Hansen à quimioterapia. in Anais do VIII Congresso Internnacional de Leprologia. Rio de Janeiro, 1963. pgs. 414-437.
32. W ORDL HEALTH ORGANIZATION. Dapsone-resistant leprosy-The THELEP approach. Int. J. Leprosy 49(4):421-25, 1981.
2. BAOHONG, J.; JIAKUN, Z.; YUHONG, H.; GUOXING, N.; & RENBAO, Z. Secondary dapsone resistant leprosy in Shangai municipality. Leprosy Rev. 54:197-202,1983.
3. BAQUILON, G.; FERRACCI, C.; VAN-LOO, G.; PATTYN, S.R. Further results on dapsoneresistant leprosy in Bamako (Mali). Leprosy Rev. 54:19-21, 1983.
4.BECHELLI, L.M. Experiência brasileira com a sulfonoterapia: relatório do Dispensário nº 2 da sede do D.P.L. Arq. min. Leprol.
12(4):286-294, 1953,
5.BOURLAND, J.; VAN-LOO, G.; & PATTYN, S.R. Dapsone resistant leprosy in Burundi. Leprosy Rev. 54:239-42, 1983.
5. CHAUSSINAND, R. Aspect atue) du probleme de la lepra. Mt. J. Leprosy20(2): 229-238, 1952.
7. CONGRESSO INTERNACIONAL DE LEPROLOGIA, 6º, MADRID, 1953, Memórias, Madrid, 1953.
7. CONGRESSO INTERNACIONAL DE LEPROLOGIA, 7º , TOKIO, 1958, Memórias. Toldo, 1958.
9. COSTA, H.C.; SOUZA, L.C.D.; SAVRON, V.B.; PRADO, D.A.C. & LOSNAK, L.M. Procedimentos utilizados para a manutenção de linhagem isogênica decamundongos Mus musculus, estirpe BALB/c, para o uso no estudo da resistência do Mycobacterium leprae à
Diamino difenil sulfona (DDS) Salusvita 8(1):69-71, 1989.
10. COSTA, H.C.; LOSNAK, L.M.; MADEIRA, S.; COELHO, A.A.M.; WINCE, P.S.; SAVRON, V.B. Curva de crescimento padrão do
Mycobacterium leprae em coxim plantar de camundongos Mus musculus, estirpe BALB/c, isogênicos, do biotério do Instituto
Lauro de Souza Lima, Bauru, Estado de São Paulo. Salusvita 9(1):01-07, 1990.
11. DAVEY, T.F. Progress with new anti-leprosy drugs. In: International Leprosy Congress, 7°, Tokio, 1958, Transactions, Tokio, 1959.
p. 252-259.
12. DAVIDSON, J.A. Isoniazid alone and combined with triosemicarbazone. Leprosy Rev. 24:104-106, 1955.
13. FLOCH, H. La sulfone resistance de bacile de Hansen. Arch. Inst. Pasteur Guyane French.429: 1947.
14. GARROD, J.M.B. Colonial Medical Research Committe, 15th Annual Report, 1959, 1960. nº 2 da sede do D.P.L. Arq. min. Leprol.
12(4):286,1953.
15. GUINTO,R.S.; CELLONA, R.V.; FAJARDO, T.T. & CRUZ, E.C. dela. Primary dapsone resistant leprosy in Cebu, Philipines. Int. J. Leprosy 49(4): 427-430, 1981.
16. JOPLING, R. The treatment of leprosy. Pos graduated Medical Journal 136: 634, 1960.
17. LEVY, L.; RUBIN, G.S. & SHESKIN, J. The prevalence of dapsone resistant leprosy in Israel. Leprosy Rev, 4&107-12, 1977.
18. LOWE, J. The treatment of leprosy with TBI/698: A report based on 38 months experience. Leprosy Rev. 24:186-199, 1954.
19. MARIANO, J. Dez anos de experiência com a sulfonoterapia. Arq. min. Leprol. 16(2):93-107, 1956.
20. MEADE, T.W.; PEARSON, J.M.H.; REES, R.J.W. & NORTH, W.R.S. The epidemiology of sulphone resistant leprosy. Int. J. Leprosy 41(4):684, 1973.
21. MIRANDA, R.N. Recaída de caso de lepra lepromatosa. Arq. Paranaense de Leprol, 2(2):51, 1953.
22. MOURA, A.M. & ROCHINE, S. Vinte casos de recaída entre doentes transferidos para tratamento ambulatorial. Arq. Paranaense
de Leprol. 2(2): 47, 1953.
23. OPROMOLLA, D.V.A. Terapêutica multidroga. An. bras. Dermatol 65(1):37-40, 1990.
24. PEARSON, J.M.H.; HAILE, G.S.; BARNETSON, R.St.C. & REES, R.J.W. Dapsone-resistant leprosy in Ethiopia. Leprosy Rev. 50:183-99, 1979.
25. PEARSON, J.M.H.; REES, R.J.W.; WATERS, M.F.R. Sulphone resistance in leprosy. A review of one hundred proven clinical cases.
Lancet 2.69-72, 1975.
26. PETERS, J.H.; SHEPARD, C.C.; GORDON, G.R.; ROJAS, A.V. & ELIZONDO,D.S. The incidence of DDS resistance In lepromatous
patients in Costa Rica: their metabolic disposition of DDS. Int. J. Leprosy 44:143-51,1976.
27. PETTIT, J.H.S. & REES, R.J.W. Sulfone resistance in leprosy. An experimental and clinical study. LANCET 2. 673, 1964.
28. QUAGLIATO, R. O problema das reativações nos dispensários de lepra. Rev. bras. Leprol. 23(1): 83-113, 1955.
29. RABELLO, F.G. Simpósio sobre experiência brasileira com a sulfonoterapia. Arq. min. Leprol. 12(4):285-426, 1953.30. SHEPARD, C.C. The experimental disease that follows the injection of human leprosy bacilli into foot pads of mice. J. exp. Med. 112:445-54, 1960.
31. SOUZA LIMA, L. & ARANTES, F.R. Resistência do bacilo de Hansen à quimioterapia. in Anais do VIII Congresso Internnacional de Leprologia. Rio de Janeiro, 1963. pgs. 414-437.
32. W ORDL HEALTH ORGANIZATION. Dapsone-resistant leprosy-The THELEP approach. Int. J. Leprosy 49(4):421-25, 1981.
This journal is licensed under a Creative Commons Attribution 4.0 International License.
Downloads
Download data is not yet available.
